Biote Corp
BTMD

$7.99

1.52%

Market Cap: 242M

About: Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.

Employees: 194

Healthcare Medicinal Chemicals & Botanical Products

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

0

News positive %

of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

11% more capital invested

Capital invested by funds: $62.7M [Q4 2023] → $69.5M (+$6.74M) [Q1 2024]

0% more funds holding

Funds holding: 54 [Q4 2023] → 54 (+0) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

3.87% less ownership

Funds ownership: 37.41% [Q4 2023] → 33.53% (-3.87%) [Q1 2024]

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$6.55

18%

downside

Avg. target

$8.18

2%

upside

High target

$9

13%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Roth MKM George Kelly	13%upside $9	Buy Reiterated	13 Mar 2024
B. Riley Securities Jeff Van Sinderen	13%upside $9	Buy Initiated	20 Feb 2024
Jefferies Kaumil Gajrawala	18%downside $6.55	Buy Initiated	1 Feb 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about BTMD published over the past 30 days

Biote Schedules Second Quarter 2024 Financial Results Release and Conference Call

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Thursday, August 8, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may.

Biote Schedules Second Quarter 2024 Financial Results Release and Conference Call

Zacks Investment Research

biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable

biote Corp. (BTMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable

Zacks Investment Research

Buy 4 Stocks With Rising Cash Flows to Enrich Your Portfolio

Achieving profit is, no doubt, a company's goal, but having a healthy cash flow is imperative to its existence, development and success. So, ASC, TXO, GPRK and BTMD are worth buying.

Buy 4 Stocks With Rising Cash Flows to Enrich Your Portfolio

Zacks Investment Research

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Zacks Investment Research

Wall Street Analysts Think biote Corp. (BTMD) Could Surge 25.44%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in biote Corp. (BTMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think biote Corp. (BTMD) Could Surge 25.44%: Read This Before Placing a Bet

Zacks Investment Research

biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable

biote Corp. (BTMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable

Zacks Investment Research

biote Corp. (BTMD) Surges 10.4%: Is This an Indication of Further Gains?

biote Corp. (BTMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

biote Corp. (BTMD) Surges 10.4%: Is This an Indication of Further Gains?

Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Marci M. Donovitz, stockholder of Biote, to resolve litigation (“Donovitz Litigation”). For $60 million in the aggregate, Biote will repurchase all of the approximately 8.3 million of the Paired Interests and/or Class.

Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares

biote Corp. (BTMD) Q1 2024 Earnings Call Transcript

biote Corp. (NASDAQ:BTMD ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Simon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Marc Beer - Executive Chairman Ross McQuivey - Chief Medical Officer Conference Call Participants Les Sulewski - Truist Securities Jonna Kim - TD Cowen Kaumil Gajrawala - Jefferies George Kelly - ROTH MKM Operator Good day, and welcome to the Biote First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

biote Corp. (BTMD) Q1 2024 Earnings Call Transcript

Zacks Investment Research

Biote Corp. (BTMD) Q1 Earnings Beat Estimates

Biote Corp. (BTMD) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.94 per share a year ago.

Biote Corp. (BTMD) Q1 Earnings Beat Estimates

See News Rankings